Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Incretin injections reduce HbA1c ‘more than gliptins’

Long-acting GLP-1 receptor agonist injections are more effective at reducing HbA1c levels in diabetes patients than gliptins when added to metformin, say European researchers.

Their meta-analysis looked at 21 studies into incretin-based therapy as an add-on to metformin for 16-30 weeks, compared with short-acting GLP-1 receptor agonists or DPP-4 inhibitors.

Long-acting GLP-1 receptor agonists produced an overall mean reduction of –1.7mmol/l (1.3%) in HbA1c compared to –1.9 mmol/l (0.7%) for DPP-4 inhibitors.

Body weight was reduced by a similar extent in the two groups with GLP-1 receptor agonists but was not significantly altered in the groups taking DPP-4 inhibitors.

Study lead Dr Carolyn Deacon, senior lecturer at the department of biomedical sciences at the University of Copenhagen, said: ‘The injectable GLP-1 receptor agonists reduce body weight (whereas the DPP-4 inhibitors are weight neutral) but are also associated with a greater incidence of gastrointestinal side effects and a tendency to increase heart rate.'

Diab Obesity and Metabolism 2012, online 24 April

http://onlinelibrary.wiley.com/doi/10.1111/j.1463-1326.2012.01603.x/abstract

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say